Human data from pancreatic cancer patients indicated that DCs with features of TSLP-treated DCs and Th2-attracting chemokines were present in pancreatic tumors, and the Th2/Th1 ratio in pancreatic tumors was an independent marker of poor survival (83). The gene discussed is TSLP; the disease is familial pancreatic carcinoma.